TWST catalysts
Catalysts and events linked to TWST, newest first.
TWST stock catalysts and risks
Latest published review: 2026-10-20
| Development | Transmission channel | Evidence | Condition to watch |
|---|---|---|---|
| Twist Bioscience Surges 31% on Eli Lilly AI Drug Discovery Deal 2026-09-20 · Up | biotech platform monetization and partnership revenue expansion | Twist Bioscience stock rose 31% on Lilly TuneLab partnership. | Not recorded |
| Twist Bioscience shares gain 31% on Eli Lilly AI drug discovery pact 2026-09-20 · Up | commercial data services revenue and validation of antibody platform | Twist surged over 31% after announcing partnership with Eli Lilly for Lilly TuneLab. | Not recorded |
| Twist Bioscience Partners With Eli Lilly on TuneLab AI Drug Discovery 2026-09-19 · Up | enterprise AI partnership revenue and service margin expansion | TWST shares rose over 31% following Lilly TuneLab collaboration announcement. | Not recorded |
| Twist Bioscience Partners with Eli Lilly on AI Drug Discovery Platform 2026-09-19 · Up | high-margin AI platform licensing fee expansion | Twist joined Eli Lilly's TuneLab initiative to provide antibody characterization services, driving a 31% weekly share gain. | Not recorded |
| Twist Bioscience Partners With Eli Lilly on TuneLab AI Drug Discovery 2026-09-19 · Up | biopharma service revenue growth and enterprise AI validation | Twist partners with Eli Lilly to supply antibody characterization on Lilly TuneLab. | Not recorded |
| Twist Bioscience partners with Eli Lilly on AI-driven TuneLab drug discovery 2026-09-19 · Up | biopharma technology licensing and data services revenue growth | Shares rose over 31% on partnership disclosure with Eli Lilly. | Not recorded |
| Twist Bioscience partners with Eli Lilly on TuneLab AI discovery 2026-09-19 · Up | biotech AI discovery services revenue expansion | Twist partnered with Eli Lilly on TuneLab AI antibody discovery. | Not recorded |
| Twist Bioscience Partners with Eli Lilly on AI-Powered TuneLab Platform 2026-09-19 · Up | biotech collaboration service revenue growth | Stock gained >31% after executing AI antibody characterization agreement with Eli Lilly. | Not recorded |
Do these developments change your position?
Review TWST alongside your other holdings and identify which decision deserves attention first.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
DateCardAvg 5d
- 2026-09-20Twist Bioscience shares gain 31% on Eli Lilly AI drug discovery pactLLY TWST
- 2026-09-20Twist Bioscience Surges 31% on Eli Lilly AI Drug Discovery DealLLY TWST
- 2026-09-20Twist Bioscience shares gain 31% on Eli Lilly AI drug discovery pactLLY TWST
- 2026-09-19Twist Bioscience Rallies 31% on Eli Lilly AI Drug Discovery CollaborationTWST
- 2026-09-19Twist Bioscience Partners With Eli Lilly on TuneLab AI Drug DiscoveryLLY TWST
- 2026-09-19Twist Bioscience Partners With Eli Lilly on TuneLab AI Drug DiscoveryLLY TWST
- 2026-09-19Twist Bioscience partners with Eli Lilly on AI-driven TuneLab drug discoveryLLY TWST
- 2026-09-19Twist Bioscience partners with Eli Lilly on TuneLab AI discoveryLLY TWST
- 2026-09-19Twist Bioscience Partners With Eli Lilly on TuneLab AI Drug DiscoveryLLY TWST
- 2026-09-19Twist Bioscience Rallies 31% on Eli Lilly AI Drug Discovery CollaborationLLY TWST
- 2026-09-19Twist Bioscience Partners with Eli Lilly on AI-Powered TuneLab PlatformLLY TWST
- 2026-09-19Twist Bioscience Partners with Eli Lilly on AI Drug Discovery PlatformLLY TWST
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.